Pharmaceutical company Cipla launched RT-PCR test kit “ViraGen” last week in association with Ubio Biotechnology Systems. This test kit is approved by ICMR and uses multiplex PCR technology. It is able to detect Sars-Cov-2 N gene with high sensitivity and specificity rate. It is available in the market from today onwards.
“This test is designed for qualitative detection of nucleic acid from SARS-Cov-2 in upper and lower respiratory specimens from individuals suspected of Covid-19. This launch will help address the current testing services and capacity issues,” Cipla. ViraGen is Cipla’s third Covid19 testing kit. It has already launched antibody and antigen testing kits last year. Antigen test kit “CIPtest” and Elifast – SARS-Cov-2 IgG ELISA test kit was produced by Cipla.
“Cipla has been working relentlessly to ensure accessibility to treatments in this fight against Covid19. Guided by our core purpose of ‘caring for life’, this partnership will enable us to reach out to more people across the country at a crucial time like now,” CEO, Cipla.